Centrallink: Your Trusted Source for Tumor Marker–Based Biospecimens and Oncology Research Materials
Centrallink is committed to supporting global cancer research by providing one of the most comprehensive selections of tumor marker–associated biospecimens available today. Our platform connects researchers, diagnostic developers, and oncology-focused institutions with ethically sourced human samples enriched with clinically significant tumor marker data. By combining scientific accuracy with advanced procurement technology, Centrallink empowers research teams to accelerate breakthroughs in cancer detection, monitoring, and personalized medicine.
Tumor markers play a central role in oncology research, helping scientists evaluate disease progression, detect malignancies, and validate diagnostic assays. Centrallink’s biospecimen inventory includes tumor marker–linked serum, plasma, whole blood, FFPE tissues, fresh frozen tissues, PBMCs, and nucleic acids. Each sample is collected under strict ethical oversight and includes detailed clinical annotations—providing the data researchers need to conduct high-impact studies with confidence.
Comprehensive Tumor Marker Coverage for Multiple Cancer Types
Our catalog features tumor marker–associated biospecimens representing a wide spectrum of cancer indications. This includes markers such as CEA, CA 19-9, PSA, AFP, CA-125, CA 15-3, CA 72-4, ß-hCG, NSE, and other oncology-relevant biomarkers. These samples support research areas including gastrointestinal cancers, breast cancer, prostate cancer, ovarian cancer, liver cancer, lung cancer, and hematologic malignancies.
Each biospecimen undergoes standardized processing and quality checks to ensure reliability for downstream applications such as biomarker discovery, assay development, calibration, oncology profiling, and laboratory validation workflows. Centrallink maintains strict compliance with global ethical and regulatory requirements to protect donor integrity and ensure sample traceability.
Streamlined Procurement Designed for Oncology and Diagnostic Development
Centrallink simplifies the process of acquiring tumor marker–linked biospecimens through an intuitive digital interface that allows researchers to search, filter, and order samples within minutes. Our platform provides transparent information about tumor marker values, diagnosis, clinical metadata, specimen type, donor demographics, and disease progression. This ensures that scientists can confidently select the most relevant biospecimens for their specific research goals.
For projects requiring special criteria—such as specific tumor marker thresholds, rare cancer indications, longitudinal data, or matched specimen sets—our scientific support team offers customized procurement assistance. We collaborate with accredited clinical collection networks and biobanks worldwide to fulfill specialized requests with precision and reliability.
Supporting Innovation Across Oncology and Precision Medicine
High-quality tumor marker–associated biospecimens are essential for advancing clinical diagnostics, cancer screening tools, therapeutic development, and personalized treatment strategies. Centrallink provides the data-rich resources needed to support research in translational oncology, early disease detection, liquid biopsy development, and multi-omics analysis—including genomics, proteomics, and metabolomics.
From routine oncology markers to rare and specialized tumor indicators, Centrallink delivers the quality, compliance, and accessibility required to drive meaningful scientific progress. Our platform enables researchers to source the right biospecimens quickly and confidently, contributing to the global effort to improve cancer outcomes and advance precision medicine.